137 related articles for article (PubMed ID: 19472531)
1. [Progress in therapy for and diagnosis of diabetic neuropathies].
Baba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):779-86. PubMed ID: 19472531
[No Abstract] [Full Text] [Related]
2. [Progress in diagnosis of and therapy for diabetic polyneuropathies].
Baba M
Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1556-62. PubMed ID: 15384682
[No Abstract] [Full Text] [Related]
3. Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
Yasuda H; Hirai A; Joko M; Terada M; Kawabata T; Maeda K; Haneda M; Kashiwagi A; Maeda T; Kikkawa R
Diabetes Care; 2000 May; 23(5):705. PubMed ID: 10834436
[No Abstract] [Full Text] [Related]
4. Diabetic neuropathy: Part 2.
Gupta A; Gupta Y
J Pak Med Assoc; 2014 Jul; 64(7):846-50. PubMed ID: 25255602
[TBL] [Abstract][Full Text] [Related]
5. [Epalrestat].
Hotta N
Nihon Rinsho; 1997 Nov; 55 Suppl():204-11. PubMed ID: 9434468
[No Abstract] [Full Text] [Related]
6. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
8. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of diabetic neuropathy].
Uesaka Y
Nihon Rinsho; 2002 Oct; 60 Suppl 10():256-9. PubMed ID: 12430238
[No Abstract] [Full Text] [Related]
10. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
Schemmel KE; Padiyara RS; D'Souza JJ
J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
[TBL] [Abstract][Full Text] [Related]
12. [Development of therapeutic agents for diabetic neuropathies].
Nakamura J
Nihon Rinsho; 2005 Jun; 63 Suppl 6():614-21. PubMed ID: 15999780
[No Abstract] [Full Text] [Related]
13. [Diabetic complication].
Iwamoto Y
Nihon Rinsho; 1991 Sep; 49(9):2136-40. PubMed ID: 1960879
[No Abstract] [Full Text] [Related]
14. [Nerve flow dynamics in the pathogenesis of diabetic neuropathy].
Ueda H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():499-503. PubMed ID: 15999759
[No Abstract] [Full Text] [Related]
15. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
[TBL] [Abstract][Full Text] [Related]
16. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
[TBL] [Abstract][Full Text] [Related]
17. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
Baba M; Kimura K; Suda T; Yagihashi S;
J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
[No Abstract] [Full Text] [Related]
18. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
[No Abstract] [Full Text] [Related]
20. [Progress in diagnosis of and therapy for diabetic amyotrophy].
Kusaka H
Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1563-6. PubMed ID: 15384683
[No Abstract] [Full Text] [Related]
[Next] [New Search]
